Modelling patterns of clearance of HPV-16 infection and vaccination efficacy

Vaccine

Volumn 29, Issue 6, 2011, Pages 1270-1277

  Baussano, Iacopo ^a,b   Garnett, Geoff ^b   Segnan, Nereo ^c   Ronco, Guglielmo ^c   Vineis, Paolo ^b  

^a CPO Piemonte   (Italy)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c CPO Piemonte   (Italy)

Author keywords

Human Papillomavirus; Mathematical modelling; Vaccination

Indexed keywords

WART VIRUS VACCINE;

ADULT; ARTICLE; CHILD; DRUG EFFICACY; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNE RESPONSE; MALE; MATHEMATICAL MODEL; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; REINFECTION; SCHOOL CHILD; UTERINE CERVIX CANCER; VACCINATION; VIRAL CLEARANCE;

ADOLESCENT; ADULT; AGED; CHILD; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; UTERINE NEOPLASMS; YOUNG ADULT;

EID: 78751567986     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.11.082     Document Type: Article

References (41)

1. Franco E.L., Villa L.L., Sobrinho J.P., Prado J.M., Rousseau M.C., Desy M., et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 1999, 180(November (5)):1415-1423.
2. Ho G.Y., Bierman R., Beardsley L., Chang C.J., Burk R.D. Natural history of cervicovaginal papillomavirus infection in young women. New Engl J Med 1998, 338(February (7)):423-428.
3. Koutsky L.A., Holmes K.K., Critchlow C.W., Stevens C.E., Paavonen J., Beckmann A.M., et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. New Engl J Med 1992, 327(October (18)):1272-1278.
4. Molano M., Van den Brule A., Plummer M., Weiderpass E., Posso H., Arslan A., et al. Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. Am J Epidemiol 2003, 158(September (5)):486-494.
5. Moscicki A.B., Shiboski S., Hills N.K., Powell K.J., Jay N., Hanson E.N., et al. Regression of low-grade squamous intra-epithelial lesions in young women. Lancet 2004, 364(November (9446)):1678-1683.
6. Rodriguez A.C., Burk R., Herrero R., Hildesheim A., Bratti C., Sherman M.E., et al. The natural history of human papillomavirus infection and cervical intraepithelial neoplasia among young women in the Guanacaste cohort shortly after initiation of sexual life. Sex Transm Dis 2007, 34(July (7)):494-502.
7. Ronco G., Segnan N., Giorgi-Rossi P., Zappa M., Casadei G.P., Carozzi F., et al. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst 2006, 98(June (11)):765-774.
8. Schiffman M., Castle P.E., Jeronimo J., Rodriguez A.C., Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007, 370(September (9590)):890-907.
9. Woodman C.B., Collins S., Winter H., Bailey A., Ellis J., Prior P., et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 2001, 357(June (9271)):1831-1836.
10. Ho G.Y., Studentsov Y., Hall C.B., Bierman R., Beardsley L., Lempa M., et al. Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles. J Infect Dis 2002, 186(September (6)):737-742.
11. Viscidi R.P., Schiffman M., Hildesheim A., Herrero R., Castle P.E., Bratti M.C., et al. Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica. Cancer Epidemiol Biomarkers Prev 2004, 13(February (2)):324-327.
12. Viscidi R.P., Snyder B., Cu-Uvin S., Hogan J.W., Clayman B., Klein R.S., et al. Human papillomavirus capsid antibody response to natural infection and risk of subsequent HPV infection in HIV-positive and HIV-negative women. Cancer Epidemiol Biomarkers Prev 2005, 14(January (1)):283-288.
13. de Gruijl T.D., Bontkes H.J., Walboomers J.M., Schiller J.T., Stukart M.J., Groot B.S., et al. Immunoglobulin G responses against human papillomavirus type 16 virus-like particles in a prospective nonintervention cohort study of women with cervical intraepithelial neoplasia. J Natl Cancer Inst 1997, 89(May (9)):630-638.
14. Carter J.J., Koutsky L.A., Hughes J.P., Lee S.K., Kuypers J., Kiviat N., et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 2000, 181(June (6)):1911-1919.
15. Frazer I.H. Interaction of human papillomaviruses with the host immune system: a well evolved relationship. Virology 2009, 384(February (2)):410-414.
16. Bontkes H.J., de Gruijl T.D., Walboomers J.M., Schiller J.T., Dillner J., Helmerhorst T.J., et al. Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. II. Systemic but not local IgA responses correlate with clearance of HPV-16. J Gen Virol 1999, 80(February (Pt 2)):409-417.
17. Ho G.Y., Studentsov Y.Y., Bierman R., Burk R.D. Natural history of human papillomavirus type 16 virus-like particle antibodies in young women. Cancer Epidemiol Biomarkers Prev 2004, 13(January (1)):110-116.
18. Mayrand M.H., Coutlee F., Hankins C., Lapointe N., Forest P., de Ladurantaye M., et al. Detection of human papillomavirus type 16 DNA in consecutive genital samples does not always represent persistent infection as determined by molecular variant analysis. J Clin Microbiol 2000, 38(September (9)):3388-3393.
19. Castle P.E., Schiffman M., Herrero R., Hildesheim A., Rodriguez A.C., Bratti M.C., et al. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis 2005, 191(June (11)):1808-1816.
20. Herrero R., Castle P.E., Schiffman M., Bratti M.C., Hildesheim A., Morales J., et al. Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J Infect Dis 2005, 191(June (11)):1796-1807.
21. Sycuro L.K., Xi L.F., Hughes J.P., Feng Q., Winer R.L., Lee S.K., et al. Persistence of genital human papillomavirus infection in a long-term follow-up study of female university students. J Infect Dis 2008, 198(October (7)):971-978.
22. Rowhani-Rahbar A., Hughes J.P., Koutsky LA Difficulties in estimating the male-to-female sexual transmissibility of human papillomavirus infection. Sex Transm Dis 2008, (December).
23. Scott M., Nakagawa M., Moscicki A.B. Cell-mediated immune response to human papillomavirus infection. Clin Diagn Lab Immunol 2001, 8(March (2)):209-220.
24. Garnett G.P. An introduction to mathematical models in sexually transmitted disease epidemiology. Sex Transm Infect 2002, 78(February (1)):7-12.
25. Anderson R.M., May R.M. Infectious diseases of humans: dynamics and control 1991, Oxford University Press.
26. Garnett G.P., Bowden F.J. Epidemiology and control and curable sexually transmitted diseases: opportunities and problems. Sex Transm Dis 2000, 27(November (10)):588-599.
27. Nokes D.J., Anderson R.M. The use of mathematical models in the epidemiological study of infectious diseases and in the design of mass immunization programmes. Epidemiol Infect 1988, 101(August (1)):1-20.
28. Baussano I., Ronco G., Segnan N., French K., Vineis P., Garnett G.P. HPV-16 infection and cervical cancer: modeling the influence of duration of infection and precancerous lesions. Epidemics 2010, 2:21-28.
29. ISTAT. Available from: [last accessed: 04.12.07]. http://demo.istat.it/index.html.
30. Signorelli C., Colzani E Age at first intercourse and HPV immunization. J Prev Med Hyg 2007, 48(June (2)):37-38.
31. Signorelli C., Pasquarella C., Limina R.M., Colzani E., Fanti M., Cielo A., et al. Third Italian national survey on knowledge, attitudes, and sexual behaviour in relation to HIV/AIDS risk and the role of health education campaigns. Eur J Pub Health 2006, 16(October (5)):498-504.
32. Clayton D., Hills D. Statistical models in epidemiology 1993, Oxford University Press, New York.
33. Gustafsson L., Ponten J., Bergstrom R., Adami H.O. International incidence rates of invasive cervical cancer before cytological screening. Int J Cancer 1997, 71(April (2)):159-165.
34. Barnabas R.V., Laukkanen P., Koskela P., Kontula O., Lehtinen M., Garnett G.P. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Med 2006, 3(May (5)):e138.
35. Taira A.V., Neukermans C.P., Sanders G.D. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis 2004, 10(November (11)):1915-1923.
36. Michels K.B., zur Hausen H. HPV vaccine for all. Lancet 2009, 374(July (9686)):268-270.
37. FUTURE II Study Group Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. J Infect Dis 2007, 196(November (10)):1438-1446.
38. Paavonen J., Naud P., Salmeron J., Wheeler C.M., Chow S.N., Apter D., et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374(July (9686)):301-314.
39. Romanowski B., de Borba P.C., Naud P.S., Roteli-Martins C.M., De Carvalho N.S., Teixeira J.C., et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 2009, 374(December (9706)):1975-1985.
40. Jit M., Gay N., Soldan K., Hong Choi Y., Edmunds W.J. Estimating progression rates for human papillomavirus infection from epidemiological data. Med Decis Making 2010, 30(January-February(1)):84-98.
41. Hebert J.R., Clemow L., Pbert L., Ockene I.S., Ockene J.K. Social desirability bias in dietary self-report may compromise the validity of dietary intake measures. Int J Epidemiol 1995, 24(April (2)):389-398.